Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
Appointed director
Asset disposition
Acq. announced
NEKTAR THERAPEUTICS (NKTR) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/17/2023 SC 13G RA CAPITAL MANAGEMENT, L.P. reports a 9.8% stake in NEKTAR THERAPEUTICS
08/11/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "Nektar Therapeutics Reports Second Quarter 2023 Financial Results"
08/07/2023 8-K Investor presentation
Docs: "Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company"
07/10/2023 SC 13G/A Invesco Ltd. reports a 2.9% stake in Nektar Therapeutics
07/10/2023 SC 13G/A VANGUARD GROUP INC reports a 6.4% stake in Nektar Therapeutics
07/07/2023 SC 13G/A BlackRock Inc. reports a 4.5% stake in NEKTAR THERAPEUTICS
07/07/2023 SC 13G/A PRIMECAP MANAGEMENT CO reports a 4.3% stake in Nektar Therapeutics
07/03/2023 SC 13G CITADEL ADVISORS LLC reports a 5.1% stake in Nektar Therapeutics
06/15/2023 4 WHITFIELD ROY A (Director) has filed a Form 4 on NEKTAR THERAPEUTICS
Txns: Sold 30,000 shares @ $0.57, valued at $17.1k
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/17/2023 4 Zalevsky Jonathan (Chief R&D Officer) has filed a Form 4 on NEKTAR THERAPEUTICS
Txns: Sold 9,791 shares @ $0.72, valued at $7k
05/17/2023 4 Wilson Mark Andrew (Chief Legal Officer) has filed a Form 4 on NEKTAR THERAPEUTICS
Txns: Sold 7,543 shares @ $0.72, valued at $5.4k
05/17/2023 4 ROBIN HOWARD W (President & CEO) has filed a Form 4 on NEKTAR THERAPEUTICS
Txns: Sold 20,361 shares @ $0.72, valued at $14.7k
05/09/2023 8-K Quarterly results
Docs: "Nektar Therapeutics Reports First Quarter 2023 Financial Results"
05/05/2023 SC 13G/A BlackRock Inc. reports a 9.7% stake in NEKTAR THERAPEUTICS
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/27/2023 8-K Quarterly results
04/25/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
04/17/2023 8-K Quarterly results
04/14/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
03/13/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Nektar Therapeutics Vivian Wu"
02/28/2023 8-K Quarterly results
Docs: "Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results"
02/23/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "PRESENTATION TITLED "PHASE 2 ISLAND STUDY OF REZPEG IN SLE"",
"Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus"
02/09/2023 SC 13G/A PRIMECAP MANAGEMENT CO reports a 8.3% stake in Nektar Therapeutics
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 12.3% stake in Nektar Therapeutics Class A
02/06/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/02/2023 SC 13G/A Invesco Ltd. reports a 19.9% stake in Nektar Therapeutics
01/09/2023 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy